Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-06-28
2011-06-28
Anderson, James (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07968588
ABSTRACT:
A pharmaceutical composition for injection comprising a depsipeptide antibiotic, WAP-8294A2, as an active ingredient, which is stable and contains WAP-8294A2in high concentrations is provided. This composition comprises WAP-8294A2of the following structural formula (1) as an active ingredient and is characterized in that 2-hydroxypropyl-β-cyclodextrin or β-cyclodextrin is contained as a stabilizer or solubilizer and the pH of the composition is not adjusted. This composition is mixed with a pH-adjusting agent such as dextrose and with an infusion or diluent comprising a solution of disodium hydrogen phosphate, sodium dihydrogen phosphate, and sodium hydroxide at the time of use to prepare a solution for intravenous administration of WAP-8294A2.
REFERENCES:
patent: 5648455 (1997-07-01), Ohashi et al.
patent: 6869927 (2005-03-01), Gentz et al.
patent: 2003/0220237 (2003-11-01), Ohnaka et al.
patent: 2004/0072797 (2004-04-01), Aramwit et al.
patent: 2005/0187249 (2005-08-01), Fuji et al.
patent: 2005/0239692 (2005-10-01), Lindenblatt et al.
patent: 2006/0111432 (2006-05-01), Lee et al.
patent: 0 838 225 (1998-04-01), None
patent: 8-000273 (1996-01-01), None
patent: 10-139663 (1998-05-01), None
patent: 2003-500456 (2003-01-01), None
patent: 2003-183154 (2003-07-01), None
patent: 2003321364 (2003-11-01), None
patent: 2005-534671 (2005-11-01), None
patent: 2006-143699 (2006-06-01), None
patent: WO 00/62793 (2000-10-01), None
patent: WO 03/094889 (2003-11-01), None
Form PCT/ISA/210 (International Search Report) dated Jul. 31, 2007.
Form IPEA/409 (International Preliminary Report on Patentability) dated Apr. 25, 2008.
K. I. Harad et al., “Separation of WAP-8294A Components, A Novel Anti-Methicillin-Resistant Staphylococcus Aureus Antibiotic, Using High-Speed Counter-Current Chromatography”, J. Chromatogr A, 2001, vol. 932, No. 1-2, pp. 75-81, Abstract.
SupplementaryEuropean Search Report for EP 07 767796 (corresponding to PCT/JP2007/063003) dated Apr. 23, 2010.
Viles et al., (1996) “Multiple solution conformation of the integrin-binding cyclic pentapeptide cyclo(-Ser-D-Leu-Asp-Val-PRO-),” Eur J Bioche. 242:352-362.
Sanderson et al., (1994) “Characterization of the solution conformation of a cyclic RGD peptide analogue by NMR spectroscopy allied with a genetic algorithm approach and constrained molecular dynamics,” Int J Pept Protein Res. 43(6)588-596.
Locardi et al., (1999) Conformations and pharmacophores of cyclic RGD containing peotides which selectively bind integrin alphav, beta3, J Peptide Sci. 5(11):491-506.
Machida Haruhiko
Nakajima Hirofumi
Anderson James
Buchanan Ingersoll & Rooney P.C.
eRigen Pharmaceuticals, Inc.
Vakili Zohreh
LandOfFree
Injectable formulation of antibiotic and solution for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Injectable formulation of antibiotic and solution for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Injectable formulation of antibiotic and solution for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2620528